Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Terminated

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX

NCT03450018↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Stopped earlyChanging treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone. (Enrollment)
Phase
Phase 1 / Phase 2
Status
Terminated
Study type
Interventional
Start
10 January 2019
Expected end
16 May 2024
Enrollment
6 participants
Sites
2
Primary outcomes
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Sponsor
Other
Results posted
No
Last update
24 May 2024

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 14